{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"245"},{"groupId":"OG001","value":"236"}]}],"title":"Number of participants with TEAEs"},{"categories":[{"measurements":[{"groupId":"OG000","value":"109"},{"groupId":"OG001","value":"106"}]}],"title":"Number of participants with SAEs"}],"denoms":[{"counts":[{"groupId":"OG000","value":"255"},{"groupId":"OG001","value":"240"}],"units":"Participants"}],"description":"Number of participants with treatment-emergent adverse events (TEAEs) and serious adverse events (SAEs), which includes laboratory tests, physical exams, electrocardiogram results and vital signs","groups":[{"description":"Tislelizumab 200 mg intravenously (IV) on Day 1 every 21 days until disease progression, unacceptable toxicity, or other discontinuation criteria were met.","id":"OG000","title":"Tislelizumab"},{"description":"Investigator choice of either paclitaxel 135-175 mg /m² on Day 1 IV every 21 days or 80-100 mg/m\\^2 on a weekly schedule; docetaxel 75 mg/m\\^2 IV on Day 1 every 21 days; or irinotecan 125 mg/m\\^2 IV on Days 1 and 8 every 21 days","id":"OG001","title":"Investigator Chosen Chemotherapy"}],"paramType":"NUMBER","populationDescription":"Safety analysis set included all participants who received ≥ 1 dose of study drug","reportingStatus":"POSTED","timeFrame":"From the first dose date to 30 days after the last dose date; up to approximately 4 years and 11 months","title":"Number of Participants Experiencing Adverse Events (AEs)","type":"SECONDARY","unitOfMeasure":"Participants"}